Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity (Q43204477)

16 November 2017

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity (English)

1 reference

16 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

A A Mathias

1

1 reference

16 November 2017

P German

2

1 reference

16 November 2017

B P Murray

3

1 reference

16 November 2017

L Wei

4

1 reference

16 November 2017

A Jain

5

1 reference

16 November 2017

S West

6

1 reference

16 November 2017

D Warren

7

1 reference

16 November 2017

J Hui

8

1 reference

16 November 2017

B P Kearney

9

1 reference

16 November 2017

language of work or name

English

0 references

publication date

30 December 2009

1 reference

Clinical Pharmacology & Therapeutics

16 November 2017

1 reference

16 November 2017

87

1 reference

16 November 2017

322-329

1 reference

16 November 2017

3

1 reference

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development

16 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Induction effects of ritonavir: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

inferred from DOI database lookup

7 January 2021

based on heuristic

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.228

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2009.228

1 reference

16 November 2017

1 reference